艾拉莫德治疗原发性干燥综合征的临床应用及作用机制  

Clinical application and mechanism of iguratimod in the treatment of primary Sj?gren’s syndrome

作　　者：邹瑶 肖伟[1] 李丽华 彭丽娟 熊英 李先耀 甘海娜 丁敬韬[1] 任翔 ZOU Yao;XIAO Wei;LI Li-hua;PENG Li-juan;XIONG Ying;LI Xian-yao;GAN Hai-na;DING Jing-tao;REN Xiang(Department of Rheumatology and Immunology,The First People's Hospital of Changde City,Changde 415000,China)

机构地区：[1]常德市第一人民医院风湿免疫科,常德德415000

出　　处：《中国新药杂志》2022年第23期2329-2332,共4页Chinese Journal of New Drugs

基　　金：湖南省科技创新计划项目(2021SK50208)。

摘　　要：艾拉莫德是一种具有抗炎、抗骨吸收及免疫调节作用的新型小分子改善病情抗风湿药,多用于治疗类风湿关节炎。原发性干燥综合征目前尚无满意的治疗措施,临床上使用的药物多为经验性治疗。多项临床研究将艾拉莫德单药或与甲泼尼龙、硫酸羟氯喹、白芍总苷中的1种或2种药物联合应用于干燥综合征患者,可提高治疗总有效率、改善干燥症状、降低球蛋白、降低炎症水平及抗体水平、升高血小板、改善肺功能且不良反应发生率低。艾拉莫德可通过减轻腺体炎症及病理损伤、抑制B淋巴细胞及抗肺纤维化等多种机制发挥治疗干燥综合征的作用。Iguratimod is a novel small-molecule anti-rheumatic drug with anti-inflammatory,anti-bone resorption and immunomodulatory effects,which can alleviate disease progession.It is mostly used for the treatment of rheumatoid arthritis.There is currently no satisfactory treatment for primary Sj9 gren’s syndrome,and most of the drugs used in clinical are based on empirical treatment.A number of clinical studies have applied iguratimod alone or in combination with one or two drugs of methylprednisolone,hydroxychloroquine,and total glucosides of paeony in patients with Sj9 gren’s syndrome,which improved the total effective rate,relieved the symptoms of dryness,decreased immune globulin,decreased inflammatory and antibody levels,increased platelet counts,improved lung function with a low incidence of adverse reactions.Iguratimod exerts threrapeutic role in the treatment of Sj9 gren’s syndrome by reducing gland inflammation and pathological damage,inhibiting B lymphocytes and decreasing pulmonary fibrosis.

关 键 词：艾拉莫德 原发性干燥综合征 临床应用 作用机制 

分 类 号：R979.5[医药卫生—药品]